Literature DB >> 14995903

Signature of a silent killer: expression profiling in epithelial ovarian cancer.

Cécile Le Page1, Diane Provencher, Christine M Maugard, Véronique Ouellet, Anne-Marie Mes-Masson.   

Abstract

With the sequencing of the human genome and the simultaneous development of high-throughput strategies, cancer biologists have entered an exciting new area for gene expression analysis, with the ability to glimpse higher order patterns of genetic and epigenetic alterations in complex diseases. Ovarian cancer biologists are rising to the challenge of applying these new technologies to this silent killer, with the eventual goal of improving the quality of life and long-term survival of patients. This review provides a summary of the disease, a description of available technologies and their application to the ovarian cancer problem, as well as a discussion on the challenges and opportunities related to DNA microarray expression profiling-based research, including downstream clinical applications. Copyright Future Drugs Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14995903     DOI: 10.1586/14737159.4.2.157

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  9 in total

1.  Proteome profiling of human epithelial ovarian cancer cell line TOV-112D.

Authors:  Jean-Philippe Gagné; Pierre Gagné; Joanna M Hunter; Marie-Eve Bonicalzi; Jean-François Lemay; Isabelle Kelly; Cécile Le Page; Diane Provencher; Anne-Marie Mes-Masson; Amaud Droit; David Bourgais; Guy G Poirier
Journal:  Mol Cell Biochem       Date:  2005-07       Impact factor: 3.396

2.  High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer.

Authors:  Marcus Bernardini; Chung-Hae Lee; Ben Beheshti; Mona Prasad; Monique Albert; Paula Marrano; Heather Begley; Patricia Shaw; Al Covens; Joan Murphy; Barry Rosen; Salomon Minkin; Jeremy A Squire; Pascale F Macgregor
Journal:  Neoplasia       Date:  2005-06       Impact factor: 5.715

3.  Gene expression profiling of primary cultures of ovarian epithelial cells identifies novel molecular classifiers of ovarian cancer.

Authors:  C Le Page; V Ouellet; J Madore; F Ren; T J Hudson; P N Tonin; D M Provencher; A-M Mes-Masson
Journal:  Br J Cancer       Date:  2006-02-13       Impact factor: 7.640

4.  Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease.

Authors:  Hubert Fleury; Laudine Communal; Euridice Carmona; Lise Portelance; Suzanna L Arcand; Kurosh Rahimi; Patricia N Tonin; Diane Provencher; Anne-Marie Mes-Masson
Journal:  Genes Cancer       Date:  2015-09

5.  Utility Of Plasma circBNC2 As A Diagnostic Biomarker In Epithelial Ovarian Cancer.

Authors:  Yingchao Hu; Yapei Zhu; Wen Zhang; Jinghe Lang; Li Ning
Journal:  Onco Targets Ther       Date:  2019-11-14       Impact factor: 4.147

6.  The chemiluminescence based Ziplex automated workstation focus array reproduces ovarian cancer Affymetrix GeneChip expression profiles.

Authors:  Michael C J Quinn; Daniel J Wilson; Fiona Young; Adam A Dempsey; Suzanna L Arcand; Ashley H Birch; Paulina M Wojnarowicz; Diane Provencher; Anne-Marie Mes-Masson; David Englert; Patricia N Tonin
Journal:  J Transl Med       Date:  2009-07-06       Impact factor: 5.531

7.  BMP-2 signaling in ovarian cancer and its association with poor prognosis.

Authors:  Cécile Le Page; Marie-Line Puiffe; Liliane Meunier; Magdalena Zietarska; Manon de Ladurantaye; Patricia N Tonin; Diane Provencher; Anne-Marie Mes-Masson
Journal:  J Ovarian Res       Date:  2009-04-14       Impact factor: 4.234

8.  Influence of monolayer, spheroid, and tumor growth conditions on chromosome 3 gene expression in tumorigenic epithelial ovarian cancer cell lines.

Authors:  Neal Al Cody; Magdalena Zietarska; Ali Filali-Mouhim; Diane M Provencher; Anne-Marie Mes-Masson; Patricia N Tonin
Journal:  BMC Med Genomics       Date:  2008-08-07       Impact factor: 3.063

9.  Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.

Authors:  Razan Sheta; Magdalena Bachvarova; Marie Plante; Marie-Claude Renaud; Alexandra Sebastianelli; Jean Gregoire; Jamilet Miranda Navarro; Ricardo Bringas Perez; Jean-Yves Masson; Dimcho Bachvarov
Journal:  J Transl Med       Date:  2020-11-19       Impact factor: 5.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.